Perinatal Triphenyl Phosphate Exposure Accelerates Type 2 Diabetes Onset and Increases Adipose Accumulation in UCD-Type 2 Diabetes Mellitus Rats

Adrian J. Green^a, James L. Graham^b, Eduardo A. Gonzalez^a, Michael R. La Frano^{b,c}, Syrago-
Styliani E. Petropoulou^d, June-Soo Park^d, John W. Newman^{b,c,e}, Kimber L. Stanhope^{b,f}, Peter J.
Havel^{b,f}, Michele A. La Merrill^a

Abstract

Triphenyl phosphate (TPhP) is a flame retardant additive frequently found in consumer products and household dust. We administered 170 µg of TPhP in maternal food from gestational day 8.5 to weaning and evaluated metabolic phenotypes of 3.5 month old male and female rats, and weight-matched males up to 6 months, to assess the development of obesity and type 2 diabetes mellitus (T2DM), respectively. Perinatal TPhP exposure increased body and fat mass in 3.5 month old male and female rats, while leptin and cumulative energy intake were elevated in males and females, respectively. Independent of body mass, perinatal TPhP exposure accelerated T2DM onset in males and increased plasma non-esterified- fasting fatty acids. These observations suggest that perinatal exposure to TPhP exacerbates the development of obesity in male and female UCDavis-T2DM rats and accelerates T2DM onset in male UCD-T2DM rats.

Keywords: triphenyl phosphate, developmental exposure, diabetes mellitus, obesity, leptin, Firemaster 550, and hyperphagia

Abbreviations: TPhP-Triphenyl phosphate, DPhP-Diphenyl Phosphate, IF-inguinal fat, GF-gonadal fat, MF-mesenteric fat, BAT-brown adipose tissue, T2DM- Type 2 Diabetes Mellitus, ADA-American Diabetes Association

1. Introduction

Type 2 Diabetes Mellitus (T2DM) is a serious metabolic disease presently affecting at least 29.1 million people in the United States [1]. In 2012, the direct annual cost attributable to T2DM was more than \$176 billion, while its indirect costs exceeded \$69 billion [1]. T2DM is associated with many serious complications, including cardiovascular disease, blindness, end stage renal failure, and lower-limb amputations [1]. Worldwide, the incidence of T2DM is rising, with most of the increase occurring during the last 20 years [2,3]. Over the past 40 years the prevalence of obesity has increased globally and now more people are obese than are underweight [4]. Interestingly, people today who eat and exercise the same amount as people 20 years ago are still more obese than their counterparts were two decades ago, though the composition of their diet and their other environmental exposures may differ [5]. This provocative finding is consistent with the hypothesis that exposure to environmental pollutants may contribute to the rapid increase in the prevalence of obesity and T2DM that is not explained by dietary factors and reduced physical activity [6–8].

Numerous candidate obesogens are lipophilic pollutants, suggesting adipose tissue is either a target of toxicity or a depot where toxicants are sequestered and from which they are released [9]. Obesogenic chemicals are added to consumer products [10,11] and are dispersed into the human environment where they become ubiquitous [11,12]. Some of these chemicals eventually distribute into human lipids, such as fat and breast milk [13], raising the possibility that they could act as developmental obesogens. Indeed, exposure to the high production volume lipophilic flame retardant mixture, Firemaster 550 (FM 550), from mid gestation to

weaning resulted in increased body mass, increased circulating fasting glucose, and impaired glucose tolerance in Wistar rats (Patisaul 2013). Further, exposure to an individual component of the FM 550 technical mixture [12,14], triphenyl phosphate (TPhP), leads to lipid accumulation in mouse bone marrow stromal BMS2 cells at concentrations between 10 – 40 μ M [15].

In addition to the metabolic toxicity associated with TPhP exposure alone or as a substantial component of FM 550 [15–17], TPhP has been found in human breast milk samples from Japan, the Philippines, and Vietnam [13]. Given these prior observations, we hypothesize that developmental exposure to the commercial flame retardant TPhP will produce effects consistent with endocrine disruption, exacerbate the development of obesity and increase the rate of T2DM onset in the UCD-T2DM rat, which is a well characterized animal model of T2DM [18].

Figure 1: Study groups. (A) Obesity study design for two female and up to two male rats per litter (L) per treatment which terminated when rats were sacrificed (Sac) at 3.5 months of age (n=6-8 L). (B) Diabetes study design for two weight-matched male rats per litter per treatment which terminated when rats were sacrificed at their onset of T2DM or at 6 months of age (n=8 L). Diabetes was diagnosed with two random plasma glucose measurements of ≥ 200 mg/dL per ADA guidelines [19]. Gestational Day (G), Postnatal Day (P), Insulin tolerance test (ITT), Glucose tolerance test (GTT)

54

55 2.1 Rat Husbandry and Diabetes Surveillance

56 We used the UCD-T2DM rat model of T2DM since this rat model more closely

57 represents the pathophysiology and progression of T2DM in humans than other available

rodent models of the disease [18]. UCD-T2DM rats develop progressive hyperglycemia along with hyperinsulinemia resulting from insulin resistance at T2DM onset accompanied by β -cell dysfunction and decompensation [18]. Because the incidence of T2DM among male and female rats is 92% and 43%, respectively, with an average age of onset of diabetes of 6 months in males and 9.5 months in females [18], we only used male rats for the diabetes study (Figure 1). This model has been validated and characterized for the investigation of the pathophysiology of T2DM, as well as T2DM prevention and treatment in numerous peer-reviewed publications [18,20–22]

Animal care and maintenance was conducted in accordance with the applicable portions of the Animal Welfare Act and the U.S. Department of Health and Human Services' Guide for the Care and Use of Laboratory Animals and approved by the University of California, Davis Institutional Animal Care and Use Committee. Study rats were kept in a climate controlled room at 25°C and 45%–60% average relative humidity on a 12 hour reversed light cycle. All rats were fed Harlan diet 2018 (3.1 kcal/g, 0.57 kcal fat, 1.8 kcal carbohydrates, 0.74 kcal protein; Teklad Diets, Madison WI).

Adult non-pregnant female UCD-T2DM rats (n=16; 3 months old) were paired with males (n=10; 3-4 months old) for a 24 hour period at which point males were removed. This was defined as gestational day zero (G0) if a sperm plug was observed or if the female rats gained at least 30g over the next 7 days. The day of birth was designated postnatal day zero (P0). Pregnant dams were randomly assigned to an exposure group (n=8 per group), and received daily oral TPhP or ethanol vehicle exposure from G8 through weaning (P21) as described in section 2.2 below. Gestational length, litter size were recorded on P0 and the sex

of pups was determined and recorded on P4. Body weights of all pups in each litter were obtained periodically from P4-21.

On P4 the litters were culled to 8 pups ensuring up to 4 males and 2 females in each litter by random selection (Figure 1A & 1B). This was done to ensure consistent exposure of pups between litters [13,23]. The time it takes to develop T2DM is accelerated among UCD-T2DM rats with higher body weights on P21. Hence at weaning the largest pups were housed in same sex littermate groups of two females and up to four males as available (Figure 1A & 1B). Urine was collected from the dams using an adapted plastic wrap method outlined by Kurien [24]. Dams were placed in clean cages without bedding for at least 20 minutes then using a pipette up to 500 µl of urine was collected in ethanol rinsed glass vials and placed on ice. At weaning all dams and remaining weanlings were sacrificed (90–330 min post-exposure) by CO₂ asphyxiation and rapid decapitation.

Two male rats weighing between 350g-400g on P61, from the TPhP group and the vehicle group were weight- matched across treatments for the diabetes study to eliminate confounding effects of body mass on the association between TPhP and T2DM onset (Figure 1B). This weight range was selected because male UCD-T2DM rats that are between 350 – 400g at 8 weeks of age develop T2DM at approximately 23 weeks of age [18]. Weight- matched rats were followed until 26 weeks or until they developed T2DM, which was defined as two consecutive weekly non-fasting glucose measurements of ≥ 200 mg/dL [18] in accordance with the American Diabetes Association (ADA) guideline of diagnosing diabetes with a random plasma glucose of 200 mg/dL or higher [19]. The remaining rats were not weight-matched and followed for the 3.5 month obesity study (Figure 1A).

The terminal procedures for rats in both the obesity and diabetes studies were identical. Prior to sacrifice, rats were fasted between 8-12 hours, their body weights recorded, and blood was collected from the tail as above prior to euthanasia. Rats were anesthetized with sodium pentobarbital and euthanized with a 1mL/kg intracardiac injection of saturated potassium chloride. Once cardiac movement had stopped for 30 seconds the rat was decapitated and the hypothalamus, liver, pancreas, heart, mesenteric adipose tissue, quadriceps, kidney, gonadal adipose tissue, inguinal adipose tissue, and brown adipose tissue were collected. All tissues were removed in the order listed above, wet weighed, and snap frozen in liquid nitrogen.

2.2 Exposure

Given that FM550 contains 17% TPhP [16], our oral TPhP dose of 170 µg per day is equivalent to the amount of TPhP present in the 1 mg FM 550 /rat /day dosed over the same developmental period that produced metabolic disruption in a previous study [17]. On average an adult ingests 28 mg of dust per day [25] making oral TPhP administration highly relevant to humans [12,25]. At 28 mg of dust per day, over the course of pregnancy and breastfeeding a woman would ingest a total of 17.5 g of dust [26]. Therefore it would require only 90 µg of TPhP per gram of dust for a woman to receive 21 mg/kg of TPhP. This is the same total exposure as rats in this study and well below 1800 µg of TPhP/g of dust, which to the best of our knowledge is the maximum observed level reported from samples collected in 2007 and 2012 [12,27,28]. Triphenylphosphite (100% purity; Accustandard, New Haven, CT) was weighed

to the nearest tenth of a mg, diluted into 100% ethanol (Fisher Scientific, Pittsburg, PA), and vortex mixed to yield a dose solution of 8.5 mg/mL.

Due to their taste aversion to the treat used as a dose vehicle by Patisaul [17], we instead dispensed 20 μ L of ethanol with or without TPhP onto a ¼ mini Nilla wafer cookie vehicle (1 quarter equivalent to 1.75 kcal total, 0.65 kcal fat, 1.05 kcal carbohydrates, 0.05 kcal protein; Nabisco, East Hanover, NJ[29] and allowed the ethanol to completely evaporate before administration to UCD-T2DM rats (Figure 1A & 1B). Dams were habituated to eating the ¼ mini Nilla wafer prior to exposure from G4-7 (Figure 1A & 1B), and all rats readily consumed the ¼ mini Nilla wafer within 5 min for all groups by the onset of the exposure period.

2.3 Urine Analysis for the analysis of Diphenylphosphate (DPhP)

Urine analysis for the main and non-volatile metabolite of TPhP, diphenylphosphate (DPhP), was performed with small modifications of a method as previously described [30]. Briefly, DPhP was measured using mixed –mode anion exchange solid phase extraction and a labeled internal standard (deuterated (d_{10})-DPhP). The modifications included that only 500 μ L samples were used for each analysis rather than 1 mL and the samples had to be diluted 200 times with the elution solvent, after the clean-up preparation, due to high levels of DPhP detected (values exceeded the upper limits of the quantitation curve). The analysis was performed on a liquid chromatographic system (LC) coupled with tandem mass spectrometry (MS/MS) applying negative electrospray ionization (N-ESI). Recoveries for both DPhP and the labeled analog were 105% $\pm$ 13% and 122% $\pm$ 25%, respectively. For quality assurance purposes,

DPhP was evaluated in laboratory blanks and six levels of quality control samples (QCs) during each analysis. DPhP levels in laboratory blanks and materials averaged to 0.3 ng/mL. The method detection limit was calculated by serial dilutions of the lowest calibration standard (0.1 ng/mL) and spiked into 1 mL of pool urine samples that were processed with the whole clean up protocol. The method detection limit (MDL) was set as the lowest amount of analyte that provided a response with: a) at least 5 times the response of the matrix sample; b) both precision (relative standard deviation, RSD) and accuracy (error, %Er) $\leq 20\%$. Limit of detection (LOD) was the lowest value detected with $RSD > 3 S_o$, where S_o was the standard deviation of the signal received from a urine sample processed and analyzed three times with the same chromatographic method and detected with %Er $\leq 20\%$. Those two values for DPhP were 0.2 and 0.1 ng/mL respectively.

2.4 Metabolic and Physical Parameters

Metabolic parameters were evaluated across the lifespan as detailed here and in Figure 1A and 1B. Body weight and food intake per cage were recorded weekly in rats from the obesity and diabetes studies, from P21. Every 2 weeks body temperature was assessed in rats from the obesity and diabetes studies by inserting a thermocouple probe into the rectum (BAT-10, Physitemp, Clifton, NJ). Cumulative energy intake (kcal) was calculated as the difference in food weight divided by the number of rats that had access to it and the number of days they had access, and transformed to kcal [31].

2.4.1 Glucose.

Non-fasting blood glucose (AlphaTrak; Abbott Laboratories, Abbott Park, IL) was recorded weekly beginning in P21 aged rats from the obesity and diabetes studies. Tail blood was collected from all rats at 3 months of age fasted for between 8-12 hours to determine fasting blood glucose (AlphaTrak).

At 13 weeks of age, 1 rat/sex/litter/treatment group in both the obesity and diabetes study were randomly assigned to receive an intraperitoneal glucose tolerance test (ipGTT) (Figure 1A & 1B). The rats receiving the ipGTT were administered 1.0 g D-glucose/kg body weight after an overnight 14 hour fast, and blood was collected from the tip of the tail to determine fasting blood glucose [32] at 0, 15, 30, 45, 60, 90, and 120 minutes after the D-glucose bolus. We determined total area under the curve (AUC) using the trapezoidal approach.

At sacrifice, blood was collected from the tail of rats in the obesity and diabetes studies, after fasting for 8-12 hours (Figure 1A & 1B) to determine fasting blood glucose. Fasted plasma collected at sacrifice in the diabetes study (Figure 1B) was tested for glycated albumin (Diazyme; Powey, CA), a glycemic indicator.

2.4.2 Hormones.

At 13 weeks of age 1 rat/sex/litter/treatment group in both the obesity and diabetes studies were randomly assigned to receive an intraperitoneal insulin tolerance tests (ipITT) (Figure 1A & 1B). The rats receiving the ipITT were fasted for 4 hours and then 1.0 U Humulin R/kg body weight was administered i.p. and blood was collected from a tail cut to determine fasting blood glucose at 0, 15, 30, 45, 60, 90, and 120 minutes after the Humulin R bolus.

At sacrifice, tail blood was collected from obesity and diabetes studies- rats (Figure 1A & 1B) fasted between 8-12 hours and thyroid stimulating hormone (TSH) (Alpco Diagnostics; Boston, MA), T4 (CalBiotech; Spring Valley, CA) leptin (Meso Scale Discovery; Gaithersburg, MD), and adiponectin (Meso Scale Discovery) were evaluated with blinding to treatment. Tail blood was collected from all rats at 3 months of age (Figure 1A & 1B) and from diabetes study (Figure 1B) rats at the time of sacrifice after fasting for between 8-12 hours to determine plasma insulin by ELISA (Mercodia; Uppsala, Sweden) while blinded to treatment. HOMA-IR, an indicator of insulin resistance, and HOMA-%B, an indicator of pancreatic beta cell function, were calculated using the HOMA2 Calculator, available at <https://www.dtu.ox.ac.uk>, using fasting blood glucose and specific fasting plasma insulin [33].

2.4.3 Lipids.

All lipid measures described in this section were performed by investigators blinded to treatment. Tail blood was collected from rats in the obesity and diabetes studies at 13 weeks of age and at sacrifice, respectively, after fasting for between 8-12 hours (Figure 1A & 1B) to determine total cholesterol, total non-esterified fatty acids (NEFA), and plasma triglycerides by enzyme based colorimetry (Wako Chemicals; Richmond, VA).

Non-esterified Fatty Acid Profiling: Non-esterified fatty acids (NEFAs) were further isolated from fasted plasma, and collected from diabetes study rats, as previously described by Smedes [34] and Gladine [35]. Specifically, plasma aliquots (50 μ L) were enriched with a suite of extraction surrogates, including isotopically labeled triglycerides and phospholipids, along with rare cholesteryl esters and fatty acids as previously reported (Grapov, Adams, Pedersen,

208 Garvey, & Newman, 2012). Lipids were then extracted twice with 10:8:11 cyclohexane/2-
209 propanol/1M ammonium acetate (v/v/v), and the organic extract was dried and reconstituted
210 in 2:1 methanol/toluene (v/v), including pentadeca-(10Z)-enoic acid (Nu-Check Prep Inc.) to
211 track methylation efficiency. Fatty acids were derivatized with 2M (trimethylsilyl) diazomethane
212 (Sigma-Aldrich, St. Louis, MO) in hexanes, reduced to dryness and reconstituted in hexane
213 containing methyl tricosanoate (Nu-Chek Prep) and analyzed by GC-MS on an Agilent
214 6890/5973N MSD (Agilent Technologies, San Jose, CA) with electron impact ionization using a
215 30m x 0.25mm x 0.25 μ m DB-225ms to separate analytes. Quantification was accomplished with
216 ChemStation vE.02.14 (Agilent Technologies, Santa Clara, CA) using internal standard
217 methodologies.

218 Lipid Mediator Profiling: Non-esterified oxylipins, endocannabinoids, endocannabinoid-
219 like monoacylglycerols and N-acylethanolamines, and nitrated fatty acids were quantified by
220 tandem quadrupole mass spectrometry using slight modifications of previously reported
221 methods [36]. Briefly, analytes were isolated from hypothalami collected from female obesity
222 study rats, as previously described [37] but without ester hydrolysis. Hypothalamus aliquots
223 (~20-25 mg) aliquots were enriched with isotopically labeled surrogates and extracted with
224 1:10:5 methanol/ethyl acetate/deionized water (v/v/v). Extracts were dried under vacuum, re-
225 constituted in 1:1 MeOH/acetonitrile (v/v) containing internal standards, and filtered at 0.1 μ m
226 through a PVDF membrane. Analytes were separated on a 2.1 x 150 mm, 1.7 μ m Acquity UPLC
227 BEH column and detected by negative mode (oxylipins and nitrated fatty acids) and positive
228 mode (endocannabinoids and endocannabinoid-like compounds) electrospray ionization using
229 multiple reaction monitoring on an API 4000 QTrap (Sciex, Framingham, MA, USA). Analytes

were quantified against calibration curves and correcting for surrogate losses using Sciex MultiQuant version 3.0.2.

2.5 Semi-quantitative PCR

The RNeasy kit (Qiagen; Hilden, Germany) was used to extract mRNA from aliquots of pulverized mesenteric fat to be used in reverse transcription PCR (Applied Biosystems; Foster City, CA) and semi-quantitative PCR while blinded to treatment. RNA was quantitated by absorbance at 260 nm wavelength and retained with a purity threshold > 1.8 for the 260/280 ratio (NanoQuant, Tecan; Männedorf, Switzerland). Semi-quantitative PCR was performed using SYBR Green primers: Peroxisome proliferator activated receptor gamma (*Pparg*, F: TGTGAAGGATGCAAGGGTTT, R:CATTCGCCCAAACCTGATGG), CCAAT/enhancer binding protein (C/EBP) alpha (*Cebpa*, F:TGCGCAAGAGCCGAGATAAA, R:GCGGTCATTGTCACTGGTCA), CCAAT/enhancer binding protein (C/EBP) beta (*Cebpb*, F:CAAGATGCGCAACCTGGAGA, R:AGCTGCTTGAACAAGTTCCG) in mesenteric fat using beta actin (*Actb*, F:CTGACAGGATGCAGAAGGAG, R:GATAGAGCCACCAATCCACA) as an endogenous control; the endogenous control did not vary significantly across treatment groups. All primers were designed for *Rattus norvegicus* by querying the Pubmed gene library with the NCBI Primer-BLAST tool [38]. Primers were designed to span an exon-exon junction with each pair separated by at least one intron in the corresponding genomic DNA. The 2^{-ddCT} method was used to approximate relative transcript fold change between treatment groups [39].

2.6 Statistical Analyses

Relative tissue weights were determined by dividing each tissue weight by body weight. Metabolic parameters were statistically analyzed as follows to determine means $\pm$ standard error of the mean (SEM) at a significance threshold of $P < 0.05$. Analyses of non-fasting blood glucose, HOMA-IR, HOMA-%B, body weight, temperature, tissue weights, relative tissue weights, TSH, adiponectin, insulin, triglycerides, cholesterol, total NEFA, and RNA expression were assessed by modeling the fixed effect of perinatal TPhP and the random effect of litter while stratifying by sex and study group shown in figures 1A and 1B using fixed effects for treatment and litter as a repeated event (PROC MIXED, SAS). All mixed models used LSMEANS to find the mean and SEM and PDIF to test significance. We also tested for sex interactions at threshold $p < 0.1$ and if it was significant it was included in the model statement in addition to the sex-stratified models described above. The distribution of the data was checked for normality before T-tests were used to evaluate gestation length, litter size, sex ratio, dam body weight, luciferase E2, cumulative energy intake, and targeted lipids because only one rat per litter was included (PROC TTEST, SAS). ITTs and GTTs were evaluated by stratifying by sex and study group (Fig 1) without random effects because only one rat per litter was included (PROC GLM, SAS). We evaluated whether perinatal TPhP accelerated the onset T2DM by using survival analysis with treatment as a fixed effect and litter as a repeated event (PROC LIFETEST, SAS). This the best method of analyzing differences in the onset of T2DM because survival analysis accounts for the non-normal distribution of time to event data and can account for censoring, that is, ending the observation period before all rats have developed T2DM.

3. Results

3.1 Perinatal TPhP is not overtly toxic

We examined the dams and pups through weaning to determine if any gross maternal or developmental TPhP toxicity was present at this dose. No significant differences were observed in the length of gestation, litter size, sex ratio, or the body weight of the dams or pups at weaning (Table 1), suggesting that exposure to TPhP was not overtly toxic with respect to these

parameters.

Table 1. Gestation and Pre-weaning

Outcome	Vehicle Control	Treatment (TPhP)
Gestation Length (days)	22.9 ± 0.1	23.6 ± 0.5
Litter Size	13.6 ± 0.8	13.3 ± 0.8
Sexes per Litter (P4)	♂6.9 ± 0.7 ♀6.1 ± 0.8	♂5.5 ± 1.0 ♀6.5 ± 0.5
Pup BW at weaning (g)	♂57.2 ± 3.1 ♀54.1 ± 3.5	♂57.0 ± 3.6 ♀53.8 ± 4.6
Dam BW at weaning (g)	330.4 ± 7.9	334.0 ± 4.3
Dam TPhP metabolite (DPhP) in urine at weaning (ng/mL)	2.6 ± 0.6	2778.0 ± 2104.0

8 Dams per exposure group: gestation length, litter size, sex ratio, or Dam body weight at sacrifice.
3 Dams per exposure group : DPhP. Table depicts means ± SEM

3.2 Perinatal exposure to TPhP increases energy intake and body weight

Figure 2: Weekly physical measurements of male and female UCD-T2DM rats, obesity study. (A) Female body weight from 3-15 weeks (n=8 TPhP and n=8 Veh exposed litters, treatment x age, $p_{\text{interaction}} < 0.05$). (B) Female cumulative energy intake (n=8 TPhP and n=8 Veh exposed litters). (C) Male body weight from 3-15 weeks (n=6 TPhP- and n=7 Veh exposed litters, treatment x age $p_{\text{interaction}} < 0.01$). (D) Male cumulative energy intake (n=6 TPhP and n=7 Veh exposed litters). Figure depicts means $\pm$ SEM.
* $p < 0.05$, ** $p < 0.01$

Food intake and body weight were measured weekly in rat offspring and the cumulative energy intake was calculated per rat (Figure 2B & 2D). In both female and male rats, those with perinatal TPhP exposure had

significantly higher body weights compared with the vehicle-treated control rats starting at week 9 and week 13, respectively ($p < 0.05$; Figure 2A & 2C). This effect of TPhP became more marked as the animals aged (treatment x age interaction $p_{\text{interaction}} < 0.05$, and < 0.01 for females and males, respectively). We also observed that the cumulative energy intake was higher in the female rats exposed to TPhP (7.8%, $p < 0.05$, Figure 2B) but not in the male rats (Figure 2D).

Because core body temperature contributes 60-90% to total energy expenditure [40], we measured core body temperature to evaluate whether perinatal TPhP exposure also modified energy expenditure. Temperature measurements taken biweekly were not significantly different across treatments in the obesity study (Supplemental Figure 1). These data show that both male and female rats perinatally exposed to TPhP had significantly elevated body weight that was at least partially explained by increased caloric intake in female rats.

3.3 Perinatal TPhP exposure increases adult rat fat pad weights

308 Given that body weight is a non-specific assessment of adiposity, tissues were collected
309 to assess changes in the weight of adipose depots, as well as evidence of overt toxicity,
310 associated with perinatal TPhP exposure. No differences in the weights of tissues collected
311 were observed across treatment groups in female pups sacrificed at weaning (Supplemental
312 Table 1). No difference was seen
313 between vehicle and treatment in both
314 the absolute and relative weights of
315 livers, quadriceps muscle, heart, or
316 pancreas collected at sacrifice in both
317 male and female adult rats in the obesity
318 study (Supplemental Figure 2A and 2B).
319 The kidney weight relative to total body
320 weight was significantly decreased ($p <$
321 0.05) in the treated adult male rats in the
322 obesity study however the absolute
323 weight was not significantly different
324 between treatments (Supplemental

Figure 3: Fat pads and qPCR quantification from male and female UCD-T2DM rats euthanized when 3.5 months old, obesity study. (A) Weights of individual fat deposits relative to body weight (B). qPCR quantification of master regulators of adipogenesis in mesenteric fat from adult rats. Inguinal Fat (IF), Gonadal Fat (GF), Mesenteric Fat (MF), Brown Adipose Tissue (BAT). Figure depicts means $\pm$ SEM

* $p < 0.05$

Figure 2A and 2B). Overall these results suggest there was no overt toxicity to non-adipose tissues of rats exposed to TPhP.

Significant changes were observed in the mean weight of fat depots collected from both male and female adult rats in the

obesity study (Figure 3A). In the adult female rats, the mean absolute weights of mesenteric fat and brown adipose depots were significantly increased in the TPhP- exposed group vs. vehicle control ($p < 0.05$, Supplemental Figure 2A) but after adjusting for body weight only the mesenteric fat remained larger (17%) in the female rats with perinatal TPhP exposure ($p < 0.05$, Figure 3A). In the adult male rats, the absolute inguinal fat, gonadal fat and mesenteric fat weights were significantly increased in the TPhP exposed group vs. vehicle controls ($p < 0.05$, Supplemental Figure 2A) and these fat depots remained significantly larger (29%, 17%, and 26% respectively) after adjusting for total body weight ($p < 0.05$, Figure 3A). Further, independent of sex, both the relative inguinal and mesenteric fat pads were significantly increased in the rats prenatally exposed to TPhP compared with vehicle-treated control animals ($p < 0.05$, Figure 3A). These results demonstrate that perinatal TPhP exposure increased body adiposity and the size of multiple fat pads in both male and female rats particularly in high risk sites such as inguinal and mesenteric fat pads. Further the data show that males accumulate more fat in these areas than females.

Figure 4: Glucose and insulin tolerance tests performed at 3 months of age on male and female UCD-T2DM rats, obesity study. (A, C) Plasma glucose excursion in response to intraperitoneal glucose administration (1 g/kg body weight and 75% D-glucose solution) in nondiabetic rats after an overnight fast. Inset shows area under the curve. (B, D) Plasma glucose excursions in response to intraperitoneal insulin administration (0.5 U/kg body weight and 1U/mL insulin solution) in nondiabetic rats after an overnight fast. Inset shows fasting insulin adjusted for body weight. $P_{\text{interaction}} < 0.1$ for treatment and sex tested on AUC. Figure depicts means $\pm$ SEM. (n=6-8L)

3.4 Perinatal TPhP exposure does not alter glucose, insulin, or lipids in early adulthood

Because we have reported that body weight is a determinant of the timing of T2DM onset in this rat model [18], we suspected that increased adiposity of 3 month old rats perinatally exposed to TPhP could lead to abnormalities in glucose and lipid homeostasis. However, fasting lipids (Supplemental Figure 4) and glucose (Figure 4) were not different between treatments in either male or female rats. Further, glucose responses during insulin and glucose tolerance tests were not significantly different between treatments in either male or female rats (Figure 4). No difference was observed in areas under the curve for the glucose tolerance test (Figure 4A & 4B inset). These data suggest that despite increased adiposity in animals exposed to perinatal TPhP, glucose, insulin, and lipids were not altered in early adulthood.

3.5 Perinatal TPhP does not alter thyroid hormones

Previous studies have reported that FM 550 is capable of increasing total T4 in rat dams [17]. Therefore we examined whether perinatal TPhP disrupts the thyroid hormone axis of rats in the obesity study. We found that total T4 tended to be lower in the male rats perinatally exposed to TPhP ($p = 0.08$, Figure 5) and no significant differences were observed in TSH for the male and female rats perinatally exposed to TPhP (Figure 5). These data suggest that increased adiposity by perinatal TPhP exposure is not mediated through disruption of the thyroid hormone axis of adult offspring.

3.6 Perinatal TPhP exposure increases fasting leptin

Because plasma leptin levels are positively related to adiposity in both rats and humans [41–44], we suspected that perinatal TPhP exposure would be associated with increased fasting leptin in rats of the obesity study. Consistent with this suspicion, there was a doubling of plasma leptin in male rats exposed to TPhP compared with vehicle-treated control male rats while in female rats there was only a 50% increase of plasma leptin concentrations ($p_{\text{interaction}} <$

Figure 5: Hormones at sacrifice in adult male and female UCD-T2DM rats, obesity study. The $p_{\text{interaction}}=0.6, 0.006$ and 0.2379 for TSH, Leptin, and Adiponectin, respectively. (n=8 L TPhP and n=8 L Veh in exposed females and n=6 L TPhP and n=8 L Veh in exposed males). Figure depicts means $\pm$ SEM. ** $P < 0.01$ *** $p < 0.001$

0.01). Furthermore, the leptin to adipose ratio, a surrogate for leptin resistance, was 32% higher in the TPhP exposed vs. vehicle control females in the obesity study ($p < 0.05$). While the leptin to adipose ratio for TPhP exposed vs. vehicle control males in the obesity study, was 39% higher it was not significantly different, consistent with leptin resistance [45,46]. Indeed, independent of sex and body weight there was a significant increase of fasting plasma leptin concentrations ($p < 0.01$) between the vehicle and TPhP exposed rats in the obesity study (Figure 5). However, adiponectin, a hormone linked to visceral adiposity [45], was not altered by TPhP exposure (Figure 5). These measurements of adipose tissue hormones suggest that the effects of increased adiposity

resulting from perinatal TPhP exposure is specific for leptin, and do not appear to influence adiponectin.

3.7 Hypothalamic lipid mediators are unchanged by perinatal TPhP exposure

Lipid mediators, including oxylipins, nitrated fatty acids, endocannabinoids, and endocannabinoid-like compounds, were analyzed among rats of the obesity group as they have been shown to play important roles in inflammatory signaling and energy balance [47,48]. No difference in the concentrations of endocannabinoids, endocannabinoid-like compounds (Supplemental Table 2), oxylipins, or nitrated fatty acids (Supplemental Table 3) was detected in the hypothalamus of female rats in the obesity study. These data suggest that the increase in adiposity seen in female rats in the obesity study is likely not driven by changes in the hypothalamic tone of the lipid mediators measured [49].

3.8 mRNA expression markers of

adipogenesis

To assess whether the
observed increased fat mass of
rats perinatally exposed to TPhP

Figure 6: Kaplan-Meier plot of T2DM incidence in weight- matched male UCD-T2DM rats, diabetes study. Weight-matched male rats were developmentally exposed to 170ug of TPhP/day from P4 through GD21. $P < 0.05$ by log rank test with censoring at 26 weeks of age (LIFETEST).

was the result of adipocyte proliferation, we measured changes in the expression of three master regulators of adipogenesis [50]. However, we found no significant differences in the RNA expression of *Pparg*, *Cebpa*, or *Cebpb* across treatment groups in both male and female adult rats in the obesity study (Figure 3B). There was an apparent interaction between treatment and sex for *Pparg* ($p_{\text{interaction}} < 0.1$), where among rats with perinatal TPhP exposure, the males have greater *Pparg* expression than observed in females ($p < 0.05$), yet this sex difference was absent in the vehicle exposed rats (Figure 3B). There was also an interaction between treatment and sex for *Cebpa* transcript abundance ($p_{\text{interaction}} < 0.1$); yet this was driven by a non-significant trend of higher *Cebpa* in males compared to females among those exposed to TPhP during development (Figure 3B). These data suggest that the increase in adiposity of male rats might be driven by a *Pparg* mediated increase in adipogenesis.

3.9 Perinatal TPhP accelerates onset of T2DM in weight- matched male rats

To examine whether perinatal TPhP exposure accelerates the onset of T2DM, T2DM was diagnosed from two consecutive weekly non-fasting glucose measurements of $\geq 200\text{mg/dL}$, according to ADA diagnostic guidelines [19]. We found that perinatal exposure to TPhP accelerated the onset of T2DM in weight-matched male rats ($p < 0.05$ PROC LIFETEST, Figure 6). Indeed, from the first T2DM case observed to the end of the study, male rats with perinatal TPhP exposure had a higher prevalence of T2DM than control rats independent of body mass.

420 For example, by 26 weeks when the study was censored, 79% of male rats perinatally exposed
 421 to TPhP developed T2DM while only 33% of the vehicle treated rats developed T2DM.
 422 Consistent with the first case of T2DM of the study being observed in 116 day old rats with
 423 perinatal TPhP exposure, no difference in GTT or ITT was observed in the 3 month old weight
 424 matched males (Supplemental Figure 5). Because of the much longer latency of T2DM onset in
 425 female UCD-T2DM rats, we made an *a priori* decision to exclude female rats from the diabetes
 426 study (Figure 1B) [18], and unfortunately cannot extend our observation of early
 427 T2DM onset to female rats here.

428 *3.10 No effect of perinatal TPhP exposure on adiposity or energy balance in weight-matched*
 429 *male rats*

430 Although male rats were weight-matched between exposure groups for the diabetes
 431 study when they were 2 months of age (Figure 1B), because of our earlier observations of

Figure 7: Physical measurements of weight-matched male UCD-T2DM rats, diabetes study. (A) Weekly body weight from 3-26 weeks (n=8 TPhP and n=8 Veh exposed litters). (B) Average daily food intake calculated from weekly measurements. Inset shows lifetime food consumption (n=8 L TPhP and n=8 L Veh exposed litters). (C) Absolute weights of all tissues collected at diabetes onset or the 6 month censor date. Figure depicts means $\pm$ SEM. *p < 0.05

adiposity resulting from hyperphagia, we considered whether increased adiposity could explain the earlier onset of T2DM in rats perinatally exposed to TPhP. However, no differences were observed for body weight, cumulative food intake, biweekly body temperature, weights of all tissues collected, or the majority of average daily food intake measurements (Figure 7, Supplemental Figure 1). These results suggest that accelerated onset of T2DM in rats following perinatal exposure to TPhP was independent of adiposity and energy balance.

3.11 Non-esterified Fatty Acids are increased by Perinatal TPhP exposure in weight-matched male rats

We conducted preliminary analyses to further characterize the metabolic profile of these rats at the end of the diabetes study. Despite the increased prevalence of diabetes in the TPhP exposed group, fasting blood glucose was significantly higher in the control group compared to the TPhP exposed group (Figure 8A, $p < 0.05$). While fasting glycated albumin was not significantly altered by treatment, its trend was consistent with the fasting blood glucose ($p < 0.1$, Figure 8A). No significant treatment differences were observed between TPhP and vehicle exposed rats in the diabetes study for fasting insulin, TSH, total T4, leptin, adiponectin, triglycerides, or cholesterol (Figure 8B-C).

Given these seeming paradoxical fasting metabolic parameters among rats with elevated prevalence of T2DM, we evaluated HOMA-IR and HOMA-%B to determine if the relationship between fasting glucose and insulin revealed insulin resistance and beta cell dysfunction, respectively. We found that perinatal exposure to TPhP had no impact on HOMA-%B, indicating beta cells had not yet become impaired at this early stage of T2DM (Figure 8D). However, perinatal TPhP exposure elevated HOMA-IR, consistent with insulin resistance (Figure 8D).

Further consistent with insulin resistance, we found that total NEFA was significantly increased among fasting rats perinatally exposed to TPhP compared to their weight-matched

Figure 8: Fasting blood analysis of weight- matched male UCD-T2DM rats at sacrifice, diabetes study. (A) Glucose and glycated albumin. (B) Triglycerides, Cholesterol, and Non-Esterified Fatty Acids (NEFA), (C) Insulin, Thyroid Stimulating Hormone (TSH), Total T4, Leptin, and, Adiponectin and (D) HOMA-%B and HOMA-IR. Figure depicts means $\pm$ SEM. * $p < 0.05$

controls in the diabetes study (Figure 8B). To further evaluate changes in total NEFA, we quantified individual fatty acids in weight- matched male rats from the diabetes study. Perinatal TPhP exposure significantly increased plasma concentrations of a number of fatty acids including palmitic acid, cis-9-palmitoleic acid, oleic acid, and cis-vaccenic acid ($p < 0.05$) while linoleic acid, gamma-linolenic acid, and alpha-linolenic acid along with the stearic acid-palmitic acid and oleic acid-stearic acid ratios were all approaching significance ($p < 0.1$, Table 2). Because of

Table 2: Non-esterified fatty acid measured in plasma from male rats, diabetes study

Metabolite (μM)	Vehicle Control	Treatment (TPhP)
<u>Saturated</u>		
Pentadecylic acid (15:0)	1.8 ± 0.1	1.9 ± 0.1
Palmitic acid (16:0)	190 ± 10	220 ± 10 *
Margaric acid (17:0)	1.33 ± 0.04	1.46 ± 0.07
Stearic acid (18:0)	38 ± 1	41 ± 2
Arachidic acid (20:0)	0.66 ± 0.04	0.65 ± 0.03
<u>Mono-Unsaturated</u>		
trans-9-Palmitoleic acid (16:1n7t)	4.5 ± 0.3	4.8 ± 0.3
cis-9-Palmitoleic acid (16:1n7)	42 ± 4	57 ± 6 *
Oleic acid (18:1n9)	124 ± 6	146 ± 8 *
cis-Vaccenic acid (18:1n7)	22 ± 1	27 ± 1 **
Nonadecylic acid (19:1n7)	2.6 ± 0.4	2.6 ± 0.3
<u>n6-PUFA</u>		
Linoleic acid (18:2n6)	188 ± 9	210 ± 9
Gamma-Linolenic acid (18:3n6)	2.1 ± 0.1	2.5 ± 0.1
Eicosadienoic acid (20:2n6)	3.4 ± 0.3	3.9 ± 0.2
Dishomo-gamma-linolenic acid (20:3n6)	4.9 ± 0.4	5.5 ± 0.5
Arachidonic acid (20:4n6)	67 ± 3	68 ± 3
Docosadienoic acid (22:2n6)	0.53 ± 0.08	0.48 ± 0.06
Adrenic Acid (22:4n6)	5.7 ± 0.2	8 ± 1
Osbond acid (22:5n6)	2.6 ± 0.2	3.4 ± 0.8
<u>n3-PUFA</u>		
Alpha-linolenic acid (18:3n3)	16 ± 1	19 ± 1
Stearidonic acid (20:4n3)	0.58 ± 0.03	0.61 ± 0.04
Eicosapentaenoic acid (20:5n3)	1.67 ± 0.08	2.0 ± 0.2
Docosapentaenoic acid (22:5n3)	4.9 ± 0.3	5.9 ± 0.5
Docosahexaenoic acid (22:6n3)	42 ± 3	43 ± 3
<u>Totals</u>		
Total Saturated Fatty Acids	230 ± 10	260 ± 20 *
Total Mono-Unsaturated Fatty Acids	190 ± 10	240 ± 10 *
Total n6-PUFA	270 ± 10	300 ± 10
Total n3-PUFA	65 ± 3	70 ± 4
Total NEFA	760 ± 30	870 ± 40 *

Table depicts means $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$

these results, total saturated fatty acids, total mono-unsaturated fatty acids, and total NEFA were all significantly elevated in adult male rats following perinatal TPhP exposure (Table 2). These elevations in fatty acids after perinatal TPhP exposure are consistent with a diabetic phenotype and have been positively associated with insulin resistance and T2DM independent of body weight [51–53][36].

4. Discussion

In this study, we report that TPhP exposure during gestation and lactation increased obesity phenotypes in male and female UCD-T2DM rats well before the onset of T2DM. Independent of body mass, this perinatal TPhP exposure accelerated the onset and increased the prevalence of T2DM in male UCD-T2DM rats. While mechanisms underlying this accelerated onset of T2DM are not yet understood, consistent with our findings here, the pathophysiology of T2DM has previously been shown to be driven by insulin resistance in this rat model of T2DM [18]. Changes in free fatty acids [54,55] are recognized to contribute to impairments of glucose homeostasis. In particular, palmitic acid, cis-9-palmitoleic acid, oleic acid, and cis-vaccenic acid were increased by perinatal TPhP exposure in our diabetes study, and these fatty acids along with the stearic acid-palmitic acid have been positively linked to insulin resistance, leptin resistance, T2DM, inflammation, and heart disease [51–53,56–59]. This is the first evidence that low-level, developmental exposure to TPhP can increase the risk of developing insulin resistance and T2DM, and that this risk is linked to alterations of circulating fatty acids. Given TPhP is a major component of the second most common flame retardant applied by

polyurethane foam [11,60], a common consumer good, our results may have significant public health implications. Future studies of perinatal TPhP exposure should characterize the molecular mechanisms of its pathophysiology during the development and progression of T2DM in both male and female rats with particular attention to elucidating the seeming paradox of lower fasting glucose in the TPhP-treated rats.

The increased body and fat mass in both male and female rats following perinatal exposure to TPhP in the obesity study suggests that TPhP is an environmental obesogen. This increase in body and fat mass appeared to be the result of an energy imbalance resulting from increased cumulative energy intake in the females, with a similar trend being observed in the males. This suggests that increased appetite is the most likely contributor to increased adiposity in female rats exposed to perinatal TPhP. Moreover, the increase in body weight is the result of increased fat deposition, particularly in mesenteric fat, a visceral depot which has been linked to insulin resistance and metabolic syndrome [61,62]. While we did not measure whole body energy expenditure by calorimetry, the majority of thermogenic energy expenditure [40], as assessed by biweekly body temperature measurements, was not significantly altered by perinatal TPhP exposure (Supplemental Figure 1).

A number of hormones and receptors have been implicated in the regulation of food intake and energy metabolism, including leptin [45]. In the obesity study, plasma leptin concentrations were elevated in both male and female rats exposed to TPhP. The greater increase of plasma leptin observed in male compared with female rats is most likely due to obesity- associated leptin resistance in male rats perinatally exposed to TPhP, as indicated by

their elevated leptin to adipose ratio [42,63]. Further, along with males rats having higher basal leptin levels compared to females, the significant increase mass of all fat depots suggests a larger capacity for leptin production [43,63,64].

Our results indicated there was also an increase in the adipose expression of *Pparg* in mesenteric adipose tissue in male rats exposed to TPhP. This is consistent with *in vitro* experiments that have reported that TPhP activates *PPARG* [65]. In agreement with the observed phenotypes, exposure to other *PPARG* agonists, tributyltin or Rosiglitazone, also increased adiposity in offspring [66]. However, we know of no studies evaluating the effects of prenatal *PPARG* agonists on the risk of developing type-2 diabetes in offspring. If perinatal *PPARG* agonism has residual anti-diabetic activity, as would be expected by known pharmacological effects of *PPARG* agonists, this may help explain the paradoxical modest reduction of fasting glucose observed in the diabetic rats perinatal exposed to TPhP in this study. Future studies will need to further evaluate this possibility.

5. Conclusions

This study has demonstrated that developmental exposure to the commercial flame retardant TPhP increases adiposity in both male and female UCD-T2DM rats, most likely due to an increase of energy intake. In addition, perinatal TPhP exposure accelerates the onset of T2DM and impairs fatty acid levels in male UCD-T2DM rats independent of body weight. We have also shown that the UCD-T2DM Rat model is a valuable model for testing the effects

525 developmental exposure to environmental pollutants that can act as obesogens and disrupters
526 of metabolic homeostasis and their consequences on the development of obesity and diabetes.

527

528 **Acknowledgements/Grant Support:**

529 The NIH (ES023513, DK095980, HL107256, HL121324, U24DK092993, U24DK097154), Office of
530 Environmental Health Hazard Assessment (agreement number 13-E0014-1), the USDA (National
531 Institute of Food and Agriculture, Hatch project 1002182 and Intramural Project 2032-51530-022-
532 00D), and a multi-campus grant from the University of California Office of the President. The USDA is an
533 equal opportunity provider and employer.

534 6. References

- 535 [1] Centers for Disease Control and Prevention, National Diabetes Statistics Report: Estimates of
 536 Diabetes and Its Burden in the United States, 2014, US Department of Health and Human Services,
 537 Atlanta, GA, 2014. [http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-](http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf)
 538 [web.pdf](http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf).
- 539 [2] Imperial College London, Global Burden of Metabolic Risk Factors of Chronic Diseases, (2013).
 540 [http://www1.imperial.ac.uk/publichealth/departments/ebs/projects/eresh/majidezzati/healthmet-](http://www1.imperial.ac.uk/publichealth/departments/ebs/projects/eresh/majidezzati/healthmetrics/metabolicriskfactors/)
 541 [rics/metabolicriskfactors/](http://www1.imperial.ac.uk/publichealth/departments/ebs/projects/eresh/majidezzati/healthmetrics/metabolicriskfactors/) (accessed July 1, 2015).
- 542 [3] P. Zimmet, K.G. Alberti, J. Shaw, Global and societal implications of the diabetes epidemic, *Nature*.
 543 414 (2001) 782–787. doi:10.1038/414782a.
- 544 [4] N.R.F. Collaboration, others, Trends in adult body-mass index in 200 countries from 1975 to 2014:
 545 a pooled analysis of 1698 population-based measurement studies with 19· 2 million participants,
 546 *The Lancet*. 387 (2016) 1377–1396.
- 547 [5] R.E. Brown, A.M. Sharma, C.I. Ardern, P. Mirdamadi, P. Mirdamadi, J.L. Kuk, Secular differences in
 548 the association between caloric intake, macronutrient intake, and physical activity with obesity,
 549 *Obes. Res. Clin. Pract.* (2015). doi:10.1016/j.orcp.2015.08.007.
- 550 [6] P.F. Baillie-Hamilton, Chemical toxins: a hypothesis to explain the global obesity epidemic, *J.*
 551 *Altern. Complement. Med.* 8 (2002) 185–192.
- 552 [7] Y.C. Klimentidis, T.M. Beasley, H.-Y. Lin, G. Murati, G.E. Glass, M. Guyton, W. Newton, M.
 553 Jorgensen, S.B. Heymsfield, J. Kemnitz, L. Fairbanks, D.B. Allison, Canaries in the coal mine: a cross-
 554 species analysis of the plurality of obesity epidemics, *Proc. R. Soc. B Biol. Sci.* 278 (2011) 1626–
 555 1632. doi:10.1098/rspb.2010.1890.
- 556 [8] M.P. Longnecker, J.L. Daniels, Environmental contaminants as etiologic factors for diabetes.,
 557 *Environ. Health Perspect.* 109 (2001) 871.
- 558 [9] M. La Merrill, C. Emond, M.J. Kim, J.-P. Antignac, B. Le Bizec, K. Clément, L.S. Birnbaum, R. Barouki,
 559 Toxicological function of adipose tissue: focus on persistent organic pollutants, *Environ. Health*
 560 *Perspect.* 121 (2013) 162–169. doi:10.1289/ehp.1205485.
- 561 [10] D. Brooke, M. Crookes, P. Quarterman, J. Burns, Environmental Risk Evaluation Report: Triphenyl
 562 Phosphate (CAS no. 115-86-6), (2009).
- 563 [11] H.M. Stapleton, J.G. Allen, S.M. Kelly, A. Konstantinov, S. Klosterhaus, D. Watkins, M.D. McClean,
 564 T.F. Webster, Alternate and New Brominated Flame Retardants Detected in U.S. House Dust,
 565 *Environ. Sci. Technol.* 42 (2008) 6910–6916. doi:10.1021/es801070p.
- 566 [12] R.E. Dodson, L.J. Perovich, A. Covaci, N. Van den Eede, A.C. Ionas, A.C. Dirtu, J.G. Brody, R.A. Rudel,
 567 After the PBDE Phase-Out: A Broad Suite of Flame Retardants in Repeat House Dust Samples from
 568 California, *Environ. Sci. Technol.* 46 (2012) 13056–13066. doi:10.1021/es303879n.
- 569 [13] J.-W. Kim, T. Isobe, M. Muto, N.M. Tue, K. Katsura, G. Malarvannan, A. Sudaryanto, K.-H. Chang, M.
 570 Prudente, P.H. Viet, S. Takahashi, S. Tanabe, Organophosphorus flame retardants (PFRs) in human
 571 breast milk from several Asian countries, *Chemosphere*. 116 (2014) 91–97.
 572 doi:10.1016/j.chemosphere.2014.02.033.
- 573 [14] D.M.V. Saunders, E.B. Higley, M. Hecker, R. Mankidy, J.P. Giesy, In vitro endocrine disruption and
 574 TCDD-like effects of three novel brominated flame retardants: TBPH, TBB, & TBCO, *Toxicol.*
 575 *Lett.* 223 (2013) 252–259. doi:10.1016/j.toxlet.2013.09.009.
- 576 [15] H.K. Pillai, M. Fang, D. Beglov, D. Kozakov, S. Vajda, H.M. Stapleton, T.F. Webster, J.J. Schlezinger,
 577 Ligand binding and activation of PPAR γ by Firemaster® 550: effects on adipogenesis and
 578 osteogenesis in vitro, *Environ. Health Perspect.* 122 (2014) 1225–1232. doi:10.1289/ehp.1408111.

- [16] S.P. McGee, A. Konstantinov, H.M. Stapleton, D.C. Volz, Aryl phosphate esters within a major PentaBDE replacement product induce cardiotoxicity in developing zebrafish embryos: potential role of the aryl hydrocarbon receptor, *Toxicol. Sci. Off. J. Soc. Toxicol.* 133 (2013) 144–156. doi:10.1093/toxsci/kft020.
- [17] H.B. Patisaul, S.C. Roberts, N. Mabrey, K.A. McCaffrey, R.B. Gear, J. Braun, S.M. Belcher, H.M. Stapleton, Accumulation and Endocrine Disrupting Effects of the Flame Retardant Mixture Firemaster® 550 in Rats: An Exploratory Assessment: FM550 IS A CANDIDATE ENDOCRINE DISRUPTOR, *J. Biochem. Mol. Toxicol.* 27 (2013) 124–136. doi:10.1002/jbt.21439.
- [18] B.P. Cummings, E.K. Digitale, K.L. Stanhope, J.L. Graham, D.G. Baskin, B.J. Reed, I.R. Sweet, S.C. Griffen, P.J. Havel, Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat, *AJP Regul. Integr. Comp. Physiol.* 295 (2008) R1782–R1793. doi:10.1152/ajpregu.90635.2008.
- [19] Classification and Diagnosis of Diabetes, *Diabetes Care.* 39 (2016) S13–S22. doi:10.2337/dc16-S005.
- [20] B.P. Cummings, A. Bettaieb, J.L. Graham, K.L. Stanhope, R. Dill, G.J. Morton, F.G. Haj, P.J. Havel, Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats., *Proc. Natl. Acad. Sci. U. S. A.* 108 (2011) 14670–14675. doi:10.1073/pnas.1107163108.
- [21] B.P. Cummings, A. Bettaieb, J.L. Graham, K.L. Stanhope, M. Kowala, F.G. Haj, M.L. Chouinard, P.J. Havel, Vertical sleeve gastrectomy improves glucose and lipid metabolism and delays diabetes onset in UCD-T2DM rats., *Endocrinology.* 153 (2012) 3620–3632. doi:10.1210/en.2012-1131.
- [22] B.P. Cummings, K.L. Stanhope, J.L. Graham, J.L. Evans, D.G. Baskin, S.C. Griffen, P.J. Havel, Dietary fructose accelerates the development of diabetes in UCD-T2DM rats: amelioration by the antioxidant, alpha-lipoic acid., *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 298 (2010) R1343-1350. doi:10.1152/ajpregu.00468.2009.
- [23] E. Dimitsantos, R.M. Escorihuela, S. Fuentes, A. Armario, R. Nadal, Litter size affects emotionality in adult male rats, *Physiol. Behav.* 92 (2007) 708–716. doi:10.1016/j.physbeh.2007.05.066.
- [24] B.T. Kurien, N.E. Everds, R.H. Scofield, Experimental animal urine collection: a review, *Lab. Anim.* 38 (2004) 333–361. doi:10.1258/0023677041958945.
- [25] USEPA, Soil and Dust Ingestions - Chapter 5, in: *Expo. Factors Handb.* 2011, EPA, 2011.
- [26] CDC, FAQs | Breastfeeding | DNPAP | CDC, (2015). <http://www.cdc.gov/breastfeeding/faq/> (accessed July 6, 2015).
- [27] C.C. Carignan, W. Heiger-Bernays, M.D. McClean, S.C. Roberts, H.M. Stapleton, A. Sjödin, T.F. Webster, Flame Retardant Exposure among Collegiate United States Gymnasts, *Environ. Sci. Technol.* 47 (2013) 13848–13856. doi:10.1021/es4037868.
- [28] J.D. Meeker, H.M. Stapleton, House Dust Concentrations of Organophosphate Flame Retardants in Relation to Hormone Levels and Semen Quality Parameters, *Environ. Health Perspect.* 118 (2009) 318–323. doi:10.1289/ehp.0901332.
- [29] S.A. Ferguson, S.Y. Boctor, Use of food wafers for multiple daily oral treatments in young rats, *J. Am. Assoc. Lab. Anim. Sci. JAALAS.* 48 (2009) 292.
- [30] S.-S.E. Petropoulou, M. Petreas, J.-S. Park, Analytical methodology using ion-pair liquid chromatography–tandem mass spectrometry for the determination of four di-ester metabolites of organophosphate flame retardants in California human urine, *J. Chromatogr. A.* 1434 (2016) 70–80. doi:10.1016/j.chroma.2016.01.020.
- [31] M. La Merrill, E. Karey, E. Moshier, C. Lindtner, M.R. La Frano, J.W. Newman, C. Buettner, Perinatal Exposure of Mice to the Pesticide DDT Impairs Energy Expenditure and Metabolism in Adult Female Offspring, *PLoS ONE.* 9 (2014) e103337. doi:10.1371/journal.pone.0103337.

- [32] A.R. Ramzy, S. Nausheen, P.K. Chelikani, Ileal transposition surgery produces ileal length-dependent changes in food intake, body weight, gut hormones and glucose metabolism in rats, *Int. J. Obes.* 2005. 38 (2014) 379–387. doi:10.1038/ijo.2013.201.
- [33] J.C. Levy, D.R. Matthews, M.P. Hermans, Correct homeostasis model assessment (HOMA) evaluation uses the computer program, *Diabetes Care.* 21 (1998) 2191–2192.
- [34] F. Smedes, Determination of total lipid using non-chlorinated solvents, *The Analyst.* 124 (1999) 1711–1718. doi:10.1039/a905904k.
- [35] C. Gladine, J.W. Newman, T. Durand, T.L. Pedersen, J.-M. Galano, C. Demougeot, O. Berdeaux, E. Pujos-Guillot, A. Mazur, B. Comte, Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention, *PLoS One.* 9 (2014) e89393. doi:10.1371/journal.pone.0089393.
- [36] D. Grapov, S.H. Adams, T.L. Pedersen, W.T. Garvey, J.W. Newman, Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids, *PLoS One.* 7 (2012) e48852. doi:10.1371/journal.pone.0048852.
- [37] M.J. Picklo Sr., J.W. Newman, Antioxidant supplementation and obesity have independent effects on hepatic oxylipin profiles in insulin-resistant, obesity-prone rats, *Free Radic. Biol. Med.* 89 (2015) 182–191. doi:10.1016/j.freeradbiomed.2015.07.152.
- [38] J. Ye, G. Coulouris, I. Zaretskaya, I. Cutcutache, S. Rozen, T.L. Madden, Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction, *BMC Bioinformatics.* 13 (2012) 134. doi:10.1186/1471-2105-13-134.
- [39] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C(T)) Method, *Methods San Diego Calif.* 25 (2001) 402–408. doi:10.1006/meth.2001.1262.
- [40] L. Landsberg, Core temperature: a forgotten variable in energy expenditure and obesity?, *Obes. Rev. Off. J. Int. Assoc. Study Obes.* 13 Suppl 2 (2012) 97–104. doi:10.1111/j.1467-789X.2012.01040.x.
- [41] R.V. Considine, M.K. Sinha, M.L. Heiman, A. Kriauciunas, T.W. Stephens, M.R. Nyce, J.P. Ohannesian, C.C. Marco, L.J. McKee, T.L. Bauer, Serum immunoreactive-leptin concentrations in normal-weight and obese humans, *N. Engl. J. Med.* 334 (1996) 292–295. doi:10.1056/NEJM199602013340503.
- [42] P.J. Havel, S. Kasim-Karakas, W. Mueller, P.R. Johnson, R.L. Gingerich, J.S. Stern, Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss, *J. Clin. Endocrinol. Metab.* 81 (1996) 4406–4413. doi:10.1210/jcem.81.12.8954050.
- [43] M. Landt, R.L. Gingerich, P.J. Havel, W.M. Mueller, B. Schoner, J.E. Hale, M.L. Heiman, Radioimmunoassay of rat leptin: sexual dimorphism reversed from humans, *Clin. Chem.* 44 (1998) 565–570.
- [44] M. Maffei, J. Halaas, E. Ravussin, R.E. Pratley, G.H. Lee, Y. Zhang, H. Fei, S. Kim, R. Lallone, S. Ranganathan, Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects, *Nat. Med.* 1 (1995) 1155–1161.
- [45] P.J. Havel, A.A. Bremer, Endocrine Regulation of Energy Homeostasis: Implications for Obesity and Diabetes., in: *Obesity*, McGraw Hill, 2010.
- [46] J.R. Vasselli, P.J. Scarpace, R.B.S. Harris, W.A. Banks, Dietary Components in the Development of Leptin Resistance, *Adv. Nutr. Int. Rev. J.* 4 (2013) 164–175. doi:10.3945/an.112.003152.
- [47] D. Balgoma, A. Checa, D.G. Sar, S. Snowden, C.E. Wheelock, Quantitative metabolic profiling of lipid mediators, *Mol. Nutr. Food Res.* 57 (2013) 1359–1377. doi:10.1002/mnfr.201200840.
- [48] F.J. Schopfer, M.P. Cole, A.L. Groeger, C.-S. Chen, N.K.H. Khoo, S.R. Woodcock, F. Golin-Bisello, U.N. Motanya, Y. Li, J. Zhang, M.T. Garcia-Barrio, T.K. Rudolph, V. Rudolph, G. Bonacci, P.R.S. Baker, H.E.

- Xu, C.I. Batthyany, Y.E. Chen, T.M. Hallis, B.A. Freeman, Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions, *J. Biol. Chem.* 285 (2010) 12321–12333. doi:10.1074/jbc.M109.091512.
- [49] A.Y. Taha, F. Gao, E. Ramadan, Y. Cheon, S.I. Rapoport, H.-W. Kim, Upregulated expression of brain enzymatic markers of arachidonic and docosahexaenoic acid metabolism in a rat model of the metabolic syndrome, *BMC Neurosci.* 13 (2012) 131. doi:10.1186/1471-2202-13-131.
- [50] C.E. Lowe, S. O’Rahilly, J.J. Rochford, Adipogenesis at a glance, *J. Cell Sci.* 124 (2011) 2681–2686. doi:10.1242/jcs.079699.
- [51] W.-S. Choi, S.-H. Kim, J.-H. Chung, Relationships of Hair Mineral Concentrations with Insulin Resistance in Metabolic Syndrome, *Biol. Trace Elem. Res.* 158 (2014) 323–329. doi:10.1007/s12011-014-9946-2.
- [52] M.A. Lankinen, A. Stančáková, M. Uusitupa, J. Ågren, J. Pihlajamäki, J. Kuusisto, U. Schwab, M. Laakso, Plasma fatty acids as predictors of glycaemia and type 2 diabetes, *Diabetologia.* 58 (2015) 2533–2544. doi:10.1007/s00125-015-3730-5.
- [53] G.J. Van Woudenberg, A. Kuijsten, C.J. Van der Kallen, M.M. Van Greevenbroek, C.D. Stehouwer, E.E. Blaak, E.J.M. Feskens, Comparison of fatty acid proportions in serum cholesteryl esters among people with different glucose tolerance status: the CoDAM study, *Nutr. Metab. Cardiovasc. Dis. NMCD.* 22 (2012) 133–140. doi:10.1016/j.numecd.2010.05.008.
- [54] R. Bergman, M. Ader, Free Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus, *Trends Endocrinol. Metab.* 11 (2000) 351–356. doi:10.1016/S1043-2760(00)00323-4.
- [55] M.Z. Shrayyef, J.E. Gerich, Normal Glucose Homeostasis, in: L. Poretsky (Ed.), *Princ. Diabetes Mellit.*, Springer US, Boston, MA, 2010: pp. 19–35. http://link.springer.com/10.1007/978-0-387-09841-8_2 (accessed April 22, 2015).
- [56] S.M. Innis, Palmitic Acid in Early Human Development, *Crit. Rev. Food Sci. Nutr.* (2015) 00–00. doi:10.1080/10408398.2015.1018045.
- [57] A. Mancini, E. Imperlini, E. Nigro, C. Montagnese, A. Daniele, S. Orrù, P. Buono, Biological and Nutritional Properties of Palm Oil and Palmitic Acid: Effects on Health, *Molecules.* 20 (2015) 17339–17361. doi:10.3390/molecules200917339.
- [58] T.A.B. Sanders, Protective effects of dietary PUFA against chronic disease: evidence from epidemiological studies and intervention trials, *Proc. Nutr. Soc.* 73 (2014) 73–79. doi:10.1017/S0029665113003789.
- [59] L. Wang, A.R. Folsom, Z.-J. Zheng, J.S. Pankow, J.H. Eckfeldt, A.S. Investigators, others, Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study, *Am. J. Clin. Nutr.* 78 (2003) 91–98.
- [60] H.M. Stapleton, S. Eagle, R. Anthopolos, A. Wolkin, M.L. Miranda, Associations between Polybrominated Diphenyl Ether (PBDE) Flame Retardants, Phenolic Metabolites, and Thyroid Hormones during Pregnancy, *Environ. Health Perspect.* 119 (2011) 1454–1459. doi:10.1289/ehp.1003235.
- [61] Y.-K. Yang, M. Chen, R.H. Clements, G.A. Abrams, C.J. Aprahamian, C.M. Harmon, Human mesenteric adipose tissue plays unique role versus subcutaneous and omental fat in obesity related diabetes, *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* 22 (2008) 531–538. doi:10.1159/000185527.
- [62] H. Zhang, M.R. Sairam, Sex hormone imbalances and adipose tissue dysfunction impacting on metabolic syndrome; a paradigm for the discovery of novel adipokines, *Horm. Mol. Biol. Clin. Investig.* 17 (2014) 89–97. doi:10.1515/hmbci-2014-0002.
- [63] M. Van Heek, D.S. Compton, C.F. France, R.P. Tedesco, A.B. Fawzi, M.P. Graziano, E.J. Sybertz, C.D. Strader, H.R. Davis, Diet-induced obese mice develop peripheral, but not central, resistance to leptin., *J. Clin. Invest.* 99 (1997) 385–390. doi:10.1172/JCI119171.

- [64] A. Kennedy, T.W. Gettys, P. Watson, P. Wallace, E. Ganaway, Q. Pan, W.T. Garvey, The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure, *J. Clin. Endocrinol. Metab.* 82 (1997) 1293–1300. doi:10.1210/jcem.82.4.3859.
- [65] S.M. Belcher, C.J. Cookman, H.B. Patisaul, H.M. Stapleton, In vitro assessment of human nuclear hormone receptor activity and cytotoxicity of the flame retardant mixture FM 550 and its triarylphosphate and brominated components, *Toxicol. Lett.* (2014). doi:10.1016/j.toxlet.2014.04.017.
- [66] R. Chamorro-García, M. Sahu, R.J. Abbey, J. Laude, N. Pham, B. Blumberg, Transgenerational inheritance of increased fat depot size, stem cell reprogramming, and hepatic steatosis elicited by prenatal exposure to the obesogen tributyltin in mice, *Environ. Health Perspect.* 121 (2013) 359–366. doi:10.1289/ehp.1205701.

Supplemental Tables and Figures

Supplemental Table 1: Physical and metabolic parameters

Outcome	Vehicle Control	Treatment (TPhP)
<i>Cull</i>		
Body Weight	♂ 8.6 ± 0.5	♂ 8.4 ± 0.6
	♀ 8.0 ± 0.4	♀ 9.2 ± 0.4
Glucose	♂ 123 ± 7	♂ 120 ± 10
	♀ 121 ± 5	♀ 126 ± 4
<i>Weaning</i>		
Body Weight	♂ 52 ± 2	♂ 50 ± 2
Glucose	♂ 167 ± 3	♂ 164 ± 3
Liver	♂ 2.5 ± 0.1	♂ 2.4 ± 0.1
Heart	♂ 0.31 ± 0.01	♂ 0.29 ± 0.01
Inguinal Fat	♂ 0.73 ± 0.04	♂ 0.67 ± 0.03

Table depicts means ± SEM

Supplemental Table 2: Endocannabinoids and endocannabinoid-like compounds measured in rat hypothalamus

Endocannabinoids (pmol/g)	Parent Lipid	Vehicle Control	Treatment (TPhP)
2-Arachidonoyl glycerol (2-AG)	C20:4n6	38,000 ± 3,000	41,000 ± 3,000
1-AG	C20:4n6	3,500 ± 400	3,900 ± 400
2-Linoleoyl glycerol (2-LG)	C18:2n6	7,000 ± 2,000	6,300 ± 900
1-LG	C18:2n6	1,300 ± 100	1,150 ± 30
2-Oleoyl glycerol (2-OG)	C18:1n9	60,000 ± 10,000	52,000 ± 6,000
1-OG	C18:1n9	9,000 ± 1,000	8,000 ± 1,000
Palmitoyl ethanolamide (PEA)	C16:0	570 ± 50	540 ± 20
Stearoyl ethanolamide (SEA)	C18:0	140 ± 20	130 ± 70
Oleoyl ethanolamide (OEA)	C18:1n9	130 ± 20	120 ± 20
Linoleoyl ethanolamide (LEA)	C18:2n6	16 ± 2	15 ± 2
Dihomogammalinolenoyl ethanolamide (DGLA)	C20:3n6	1.4 ± 0.6	1.2 ± 0.6
Arachidonoyl ethanolamide (AEA)	C20:4n6	23 ± 2	19 ± 3
Docosatetraenoyl ethanolamide (DEA)	C22:4n6	11 ± 2	10 ± 2
Docosahexaenoyl ethanolamide (DHEA)	C22:6n3	56 ± 4	45 ± 6
N-Oleoyl glycine (NO-Gly)	C18:1n9	5 ± 2	5 ± 2

Table depicts means ± SEM

743

744

745

746

Supplemental Figure 1: Bi-weekly body temperature measurements from obesity and diabetes study rats. (A) Obesity study females. (B) Obesity study males. (C) Diabetes study males. Figure depicts means $\pm$ SEM.

747

748

Supplemental Figure 2: Fat pads and Tissue weights from male and female UCD-T2DM rats at 3.5 Month Sacrifice, Obesity Study. (A) Weights of individual fat pads. (B) Weights of all tissues collected. Figure depicts means $\pm$ SEM. * $p < 0.05$ ** $p < 0.01$

749 **Supplemental Table 3: Non-esterified oxylipins and nitrated fatty acids measured in rat**
750 **hypothalamus**

Non-esterified oxylipins (pmol/g)	Parent Lipid	Vehicle Control	Treatment (TPhP)
6-keto PGF1a	C20:4n6	8 ± 1	6 ± 2
TXB2	C20:4n6	19 ± 2	19 ± 2
PGF2a	C20:4n6	15 ± 2	14 ± 2
PGE2	C20:4n6	8 ± 3	7 ± 3
PGD2	C20:4n6	51 ± 5	42 ± 9
12_13-DiHOME	C18:2n6	0.07 ± 0.01	0.06 ± 0.01
9_10-DiHOME	C18:2n6	0.9 ± 0.1	0.80 ± 0.03
19_20-DiHDoPA	C22:6n3	0.8 ± 0.2	0.8 ± 0.2
14_15-DiHETrE	C20:4n6	0.3 ± 0.1	0.27 ± 0.07
11_12-DiHETrE	C20:4n6	0.3 ± 0.1	0.28 ± 0.06
9-HOTE	C18:3n3	1.0 ± 0.3	1.3 ± 0.7
13-HOTE	C18:3n3	4 ± 2	6 ± 2
12-HEPE	C20:5n3	2.2 ± 0.3	2 ± 1
13-HODE	C18:2n6	56 ± 8	60 ± 20
9-HODE	C18:2n6	31.9 ± 3.1	39.7 ± 20.5
17-HDoHE	C22:6n3	13.8 ± 1.9	18.2 ± 2.2
14-HDoHE	C22:6n3	15.9 ± 1.6	18.3 ± 2.4
11-HETE	C20:4n6	33.0 ± 3.4	30.9 ± 3.6
12-HETE	C20:4n6	111 ± 29	114 ± 25
8-HETE	C20:4n6	4.6 ± 2.1	5.0 ± 0.5
5-HETE	C20:4n6	13.5 ± 4.1	13.9 ± 2.5
5-KETE	C20:4n6	2.0 ± 0.8	1.9 ± 0.1
14(15)-EpETrE	C20:4n6	3.3 ± 1.1	3.4 ± 0.7
11(12)-EpETrE	C20:4n6	1.5 ± 0.4	1.6 ± 0.1
8(9)-EpETrE	C20:4n6	1.5 ± 0.7	1.6 ± 0.4
10-Nitrooleate	C18:1n9	7.5 ± 1.3	12.1 ± 2.1 †
15(16)-EpODE	C18:3n3	1.9 ± 1.2	2.3 ± 1.6
12(13)-EpODE	C18:3n3	0.23 ± 0.06	0.49 ± 0.1 †

751 Table depicts means ± SEM. † p < 0.1

752

753

754

755

756

Supplemental Figure 3: Body weight measurements from all pups in the obesity and diabetes study. (A) Female pups. (B) Male pups. Figure depicts means $\pm$ SEM.

757

758

Supplemental Figure 4: Fasting blood analysis of male and female UCD-T2DM rats at 3 Months, Obesity Study. (A) Female rats. (B) Male rats. Figure depicts means $\pm$ SEM. * $p < 0.05$ ** $p < 0.01$

Supplemental Figure 5: Glucose and insulin tolerance tests performed at 3 months of age on male UCD-T2DM rats, diabetes study. (A) Plasma glucose excursion in response to intraperitoneal glucose administration (1 g/kg body wt and 75% D-glucose solution) in nondiabetic rats after an overnight fast. Inset shows area under the curve. (B) Plasma glucose excursions in response to intraparotoneal insulin administration (0.5 U/kg body wt and 1U/mL insulin solution) in nondiabetic rats after an overnight fast. Inset shows fasting insulin adjusted for body weight. $P_{\text{interaction}} < 0.1$ for treatment and sex tested on AUC. Figure depicts means $\pm$ SEM.